Global X China Biotech ETF Units Thailand Depository Receipt Repr 0.01 Sh
SSET:CNBIO241.45
THB
-0.09
(-5.84%)
ISIN
TH0802120004
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Miscellaneous
- Industry
- Investment trusts
- Address
- Hong Kong
- Similar Companies
- Business
- Global X China Biotech ETF Units Thailand Depository Receipt Repr 0.01 Sh (Ticker: SET:CNBIO24) is an exchange-traded depositary receipt issued by Finansia Syrus Securities Public Company Limited and listed on the Stock Exchange of Thailand. The financial instrument provides domestic institutional and retail investors with fractional, local-currency investment access to the Global X China Biotech ETF, an exchange-traded fund managed by Mirae Asset Global Investments (Hong Kong) Limited and traded on the Hong Kong Exchanges and Clearing under stock code 2820. Each depositary receipt unit represents beneficial ownership of 0.01 shares of the underlying Hong Kong-domiciled fund. The issuer, Finansia Syrus Securities Public Company Limited, was founded in 1999 and is headquartered in Bangkok, Thailand, serving as the depositary manager, liquidity provider, and market maker for the security, while the underlying ETF was incepted in July 2019 in Hong Kong. The instrument is categorized under the financial services and cross-border asset management sector, tracking the performance of the Solactive China Biotech Index (Net Total Return). The underlying asset portfolio systematically delivers exposure to leading biotechnology, pharmaceutical, and life sciences enterprises operating across Mainland China and Hong Kong, offering diversified exposure to core industry product and service segments including innovative monoclonal antibody and oncology therapeutic development; biopharmaceutical research and drug discovery platforms; commercial-stage biological medicine manufacturing; cell and gene therapy innovations; contract research organization (CRO) services; contract development and manufacturing organization (CDMO) services; clinical immunology and vaccine production; genomics and molecular diagnostic platforms; and active pharmaceutical ingredient (API) synthesis, featuring key constituent holdings such as BeiGene, Innovent Biologics, WuXi Biologics, Legend Biotech, Akeso, Sino Biopharmaceutical, CSPC Pharmaceutical Group, Hansoh Pharmaceutical Group, and GenScript Biotech. Core services provided through the depositary receipt structure encompass seamless Thai Baht currency settlement; intraday continuous trading liquidity on the SET; cross-border custodial and asset registration management; foreign dividend pass-through and currency conversion mechanisms; and portfolio diversification into high-growth Asian biotechnology innovators without requiring foreign trading accounts. In recent operational and strategic developments, Finansia Syrus Securities listed CNBIO24 on the Stock Exchange of Thailand in December 2025 as part of an aggressive expansion of its offshore thematic depositary receipt suite designed to meet growing investor demand for specialized foreign equity exposure. Within the past two years, the underlying ETF has completed regular semi-annual benchmark index rebalancings to incorporate emerging clinical-stage biotechnology firms while optimizing weighting caps to manage single-stock concentration risk. Concurrently, Finansia Syrus Securities has expanded its digital trading distribution partnerships and market-making execution infrastructure to improve secondary market liquidity, minimize tracking error relative to the underlying Hong Kong shares, and broaden access for digital wealth platforms across Thailand.